Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
SOURCE: The Medical News – Read entire story here.
Related Posts
Busselton Jetty could be home to sea sponges with cancer-fighting compounds
A popular tourist destination in WA’s South West could also be home to sea sponges […]
Benefits of calorie restriction on par with balancing protein and carb intake in mice
Cutting calories through dietary restriction has been shown to lower cholesterol, improve insulin sensitivity, and even prolong life in mammals. Now, new research publishing on May 28th in Cell Reports shows that, at least in mice, low protein, high carbohydrate diets can provide benefits similar to those obtained with calorie restriction.
Revealed: The Ocean’s Tiniest Life At The Bottom Of The Food Chain
The ocean’s tiniest inhabitants — including bacteria, plankton, krill — are food for most everything that swims or floats. Now, scientists have completed a count of this vast and diverse hidden world.» E-Mail This